Summary: This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG (LSLS-ATAT) to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2. Modification of amino acid residues at the junction of immunocytokine fusion proteins to reduce immunogenicity by identifying candidate T-cell epitopes.
Description: This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG (LSLS-ATAT) to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2. Modification of amino acid residues at the junction of immunocytokine fusion proteins to reduce immunogenicity by identifying candidate T-cell epitopes. This immunocytokine was designed for treating solid tumor. http://www.creativebiolabs.net/Anti-EpCAM-Immunocytokine-IgG-LSLS-ATAT-huKS-IL2-22504.htm
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
